Oncodheep
Contact Us

For more information. Please complete this form.

Name
Email
Mobile Number
Message
Services
Home | Services
Haemato Oncology ?

Hematologic oncology, or hemato-oncology, is a branch of oncology that deals with cancers affecting the blood, bone marrow, lymph, and lymphatic system. This specialty includes various types of blood cancers, such as

Leukemia: A cancer of the bone marrow and blood, leading to the production of abnormal white blood cells.

  • Acute Leukemias (e.g., Acute Lymphoblastic Leukemia : ALL, Acute Myeloid Leukemia - AML).

  • Chronic Leukemias (e.g., Chronic Lymphocytic Leukemia: CLL, Chronic Myeloid Leukemia - CML).

Lymphoma: Cancers that begin in the lymphatic system.

  • Hodgkin Lymphoma

  • Non-Hodgkin Lymphoma (e.g., Diffuse Large B-cell Lymphoma - DLBCL)

Myeloma : A cancer of the plasma cells in the bone marrow, including Multiple Myeloma, which affects the production of antibodies.

Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, leading to low blood counts.

Myeloproliferative Neoplasms (MPNs): A group of diseases that involve the excessive production of blood cells in the bone marrow, such as Polycythemia Vera, Essential Thrombocythemia, and Chronic Myelogenous Leukemia.

Treatment of hematologic cancers typically involves a combination of chemotherapy, radiation therapy, stem cell or bone marrow transplantation, targeted therapies, and immunotherapy, depending on the specific type and stage of the disease.

The treatment of hematologic malignancies (blood cancers) varies depending on the type, stage, and individual patient factors, such as age, overall health, and response to prior treatments. Here’s an overview of common treatment strategies for various types of hematologic malignancies.

Leukemia
  • Acute Leukemias (e.g., Acute Lymphoblastic Leukemia [ALL], Acute Myeloid Leukemia [AML]).
  • Chemotherapy: Often the first-line treatment, involving combination regimens to induce remission.
  • Stem Cell or Bone Marrow Transplantation: For patients who relapse or have high-risk disease, a hematopoietic stem cell transplant (HSCT) may be recommended.
  • Targeted Therapy: For certain mutations (e.g., BCR-ABL in CML), tyrosine kinase inhibitors like imatinib can be effective.
  • Immunotherapy: Newer options include CAR T-cell therapy (e.g., Kymriah for ALL) and monoclonal antibodies.
  • Radiation Therapy: Used occasionally, especially in cases of CNS involvement in ALL.
  • Chronic Leukemias (e.g., Chronic Lymphocytic Leukemia [CLL], Chronic Myelogenous Leukemia [CML]).
  • CML:yrosine kinase inhibitors (TKIs) like imatinib or dasatinib target the BCR-ABL fusion gene and can be very effective.
  • CLL:Targeted therapies (e.g., ibrutinib, venetoclax) are commonly used, along with chemotherapy in some cases. Stem cell transplants are considered for relapsed/refractory cases.
  • Immunotherapy:Monoclonal antibodies such as rituximab (for CLL) can be part of the regimen.
Lymphoma
  • Hodgkin Lymphoma.
  • Chemotherapy:ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) is the standard treatment, sometimes combined with radiation therapy.
  • Radiation Therapy:Often used in limited-stage disease or after chemotherapy for consolidation.
  • Immunotherapy:PD-1 inhibitors like nivolumab and pembrolizumab have been used for relapsed/refractory disease.
  • Non-Hodgkin Lymphoma (NHL).
  • Indolent (Slow-growing) Lymphomas: For conditions like follicular lymphoma, the treatment may not be required immediately; watchful waiting is an option. When treatment is needed, chemotherapy combined with rituximab (R-CHOP regimen) is common.
  • Aggressive Lymphomas (e.g., DLBCL): Chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) are standard for treating aggressive lymphomas.
  • CAR T-cell Therapy:For relapsed/refractory cases of aggressive NHL, especially in cases that don’t respond to other treatments.
Multiple Myeloma
  • Chemotherapy and Steroids:Regimens like VCD (bortezomib, cyclophosphamide, dexamethasone) are commonly used in induction therapy.
  • Targeted Therapy:Proteasome inhibitors (e.g., bortezomib, carfilzomib) and immunomodulatory drugs (e.g., thalidomide, lenalidomide) are part of standard therapy.
  • Stem Cell Transplantation: Autologous stem cell transplant (using the patient’s own stem cells) is often performed after remission to consolidate results.
  • Immunotherapy:Monoclonal antibodies (e.g., daratumumab) targeting specific proteins on myeloma cells are increasingly used.
  • Radiation Therapy:Sometimes used for localized bone lesions or complications.
Myelodysplastic Syndromes (MDS)
  • Supportive Care:Blood transfusions, growth factors (e.g., erythropoiesis-stimulating agents), and antibiotics.
  • Chemotherapy:Hypomethylating agents like azacitidine and decitabine are often used to help control the disease.
  • Stem Cell Transplantation: HSCT may be the only curative option for high-risk MDS.
  • Immunosuppressive Therapy:In cases of refractory MDS, immunosuppressive therapy (e.g., antithymocyte globulin [ATG], cyclosporine) may be used.
Myeloproliferative Neoplasms (MPNs)
  • Polycythemia Vera (PV)
  • Phlebotomy:Regular blood removal to reduce red blood cell count.
  • Aspirin:To reduce the risk of blood clots.
  • Stem Cell Transplantation: HSCT may be the only curative option for high-risk MDS.
  • JAK2 Inhibitors:Ruxolitinib is used for controlling symptoms and reducing spleen size.
  • Essential Thrombocythemia (ET)
  • Aspirin:To prevent blood clots.
  • Hydroxyurea:Used for high-risk patients to reduce platelet count.
  • Chronic Myelogenous Leukemia (CML)
  • Tyrosine Kinase Inhibitors (TKIs):Drugs like imatinib, dasatinib, and nilotinib are effective in treating CML.
Stem Cell Transplantation (HSCT)
  • Autologous Transplantation:Using the patient’s own stem cells, often after high-dose chemotherapy to wipe out cancerous cells.
  • Allogeneic Transplantation:Using stem cells from a donor (often a sibling or unrelated donor). This is considered for high-risk or relapsed hematologic malignancies.
Immunotherapy and Targeted Therapies
  • CAR T-cell Therapy:A personalized treatment where a patient’s T-cells are modified to target cancer cells. This is increasingly used for aggressive lymphomas and certain leukemias.
  • Checkpoint Inhibitors:PD-1/PD-L1 inhibitors (e.g., nivolumab, pembrolizumab) for relapsed/refractory Hodgkin lymphoma and some other cancers.
  • Monoclonal Antibodies:These target specific proteins on cancer cells (e.g., rituximab for B-cell lymphomas, daratumumab for myeloma).
Radiation Therapy
  • Used as a Consolidation Therapy:Often used after chemotherapy to eradicate any remaining cancer cells.
  • For Localized Disease: It can also be used for localized lymph node involvement or bone lesions in multiple myeloma.

Treatment plans are highly individualized, often involving a combination of these modalities based on the specific type of hematologic malignancy, the patient’s health, and their response to prior treatments. Multidisciplinary care involving hematologists, oncologists, radiologists, and other specialists is crucial for optimal management.

Working Time
  • Mon - Tue
    -
    10:00 – 18:00
  • Wed - Thu
    -
    10:00 – 17:00
  • Fri-Sat
    -
    10:00 – 12:30
  • Sun
    -
    Closed
Need a personal health plan?
Dr.Dheepika B
Radition Oncology
+91 81221 70915
Know More
  • Have a question? call us now
    +91 81221 70915
  • Need support? Drop us an email
    info@oncodheep.com
  • We are open on
    Mon - Sat - 07:00 - 21:00
Copyright © 2024 oncodheep.com. All rights reserved.